Evidence map›Paper›PMID 42065802›Full record

ArticleActa neurologica Belgica2026

Levetiracetam- associated B-cell lymphopenia in a neonate: a rare case report.

Muhammed Ibrahim Ozsuer, Ilknur Kulhas Celik, Murat Konak, Hasibe Artac

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammed Ibrahim OzsuerDepartment of Pediatrics, Division of Immunology and Allergy, Selcuk University Medical Faculty, Konya, Turkey.ORCID http://orcid.org/0000-0002-6631-8543
Ilknur Kulhas CelikDepartment of Pediatrics, Division of Immunology and Allergy, Selcuk University Medical Faculty, Konya, Turkey. celikilknur46@gmail.com.ORCID http://orcid.org/0000-0003-3812-9654
Murat KonakDepartment of Pediatrics, Division of Neonatology, Selcuk University Medical Faculty, Konya, Turkey.ORCID http://orcid.org/0000-0001-8728-4541
Hasibe ArtacDepartment of Pediatrics, Division of Immunology and Allergy, Selcuk University Medical Faculty, Konya, Turkey.ORCID http://orcid.org/0000-0002-9807-2605

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While antiseizure medications (ASMs) exhibit the ability to influence the immune system, the specific immunosuppressive consequences in neonates remain insufficiently delineated. Levetiracetam is regarded a safe and effective second-line treatment following phenobarbital, particularly in cases where first-line agents are ineffective or result in adverse reactions in neonatal seizures. We present a neonate who developed B-cell lymphopenia due to levetiracetam administration, which constitutes a previously unrecognized adverse effect of the medication in neonates. To our knowledge, this case marks the initial documented occurrence of B-cell lymphopenia associated with levetiracetam in a neonate.

Indexed as

AnticonvulsantsB-LymphocytesLevetiracetamLymphopeniaPiracetamEpilepsyFemaleHumansInfant, NewbornMaleSeizuresAnticonvulsantsLevetiracetamPiracetamLevetiracetamLymphopeniaNeonatal epilepsy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.